Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $276

Citigroup analyst Yigal Nochomovitz has maintained a 'Buy' rating on Ligand Pharmaceuticals (NASDAQ: LGND) and raised the price target from $270 to $276. This adjustment reflects a positive outlook for the company.